Lilly CEO Dave Ricks is confident in the ability of the company's pill to compete and is preparing for a "full launch" in the ...
The plant will help make Lilly's experimental drug called retatrutide, which has shown the highest weight loss seen to date ...
Researchers reviewed the body mass index of over 11 million Americans.
The agreement to gain rights outside of China to a portfolio of experimental obesity and diabetes drugs could be valued at ...
Using data culled from nearly 11 million people, the researchers found that just over 19% were obese in 1990, compared to ...
AstraZeneca is handing $1.2 billion in upfront cash to CSPC Pharmaceuticals for the ex-China rights to the biopharma’s ...
The prevalence of obese adults in the United States more than doubled between 1990 and 2022.
As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of ...
Researchers projected that adult obesity rates in the U.S. will rise to 47% in the next decade. Multifactorial strategies ...
BERLIN, Jan 27 (Reuters) - Roche's experimental obesity drug, which works in a similar way to Eli Lilly's Zepbound, produced ...
7don MSN
What obesity drugmakers see next in the market: More pills, easier access and drug combinations
CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare ...
A new study reveals stopping GLP-1 weight loss drugs leads to rapid weight regain, nearly four times faster than quitting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results